FY2022 EPS Estimates for Repligen Co. (NASDAQ:RGEN) Cut by KeyCorp

Repligen Co. (NASDAQ:RGENGet Rating) – Research analysts at KeyCorp reduced their FY2022 EPS estimates for shares of Repligen in a research note issued to investors on Wednesday, April 27th. KeyCorp analyst P. Knight now anticipates that the biotechnology company will post earnings per share of $3.10 for the year, down from their prior estimate of $3.25. KeyCorp also issued estimates for Repligen’s FY2023 earnings at $3.50 EPS.

Repligen (NASDAQ:RGENGet Rating) last released its quarterly earnings results on Wednesday, April 27th. The biotechnology company reported $0.92 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.72 by $0.20. The business had revenue of $206.40 million during the quarter, compared to analyst estimates of $185.48 million. Repligen had a net margin of 19.86% and a return on equity of 11.26%. The company’s quarterly revenue was up 44.5% on a year-over-year basis. During the same period in the prior year, the firm posted $0.68 earnings per share.

Several other equities analysts have also commented on the stock. SVB Leerink decreased their price objective on shares of Repligen from $275.00 to $250.00 and set an “outperform” rating for the company in a research report on Friday, February 18th. Craig Hallum decreased their price objective on shares of Repligen from $286.00 to $274.00 in a research report on Thursday. StockNews.com started coverage on shares of Repligen in a report on Thursday, March 31st. They issued a “hold” rating on the stock. Finally, Zacks Investment Research downgraded shares of Repligen from a “buy” rating to a “hold” rating and set a $190.00 price target on the stock. in a report on Monday, February 21st. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Buy” and an average target price of $279.88.

Shares of Repligen stock opened at $157.24 on Monday. The firm has a market capitalization of $8.56 billion, a P/E ratio of 62.15 and a beta of 0.90. The company has a 50 day moving average price of $173.16 and a 200 day moving average price of $217.42. Repligen has a 52 week low of $138.40 and a 52 week high of $327.32.

In related news, Director Thomas F. Ryan, Jr. sold 2,000 shares of the company’s stock in a transaction that occurred on Tuesday, March 1st. The stock was sold at an average price of $198.03, for a total value of $396,060.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 1.20% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the business. HM Payson & Co. purchased a new stake in Repligen in the fourth quarter valued at approximately $26,000. Confluence Wealth Services Inc. purchased a new stake in Repligen in the fourth quarter valued at approximately $27,000. Assetmark Inc. purchased a new stake in shares of Repligen during the third quarter worth approximately $49,000. Sageworth Trust Co of South Dakota acquired a new position in Repligen during the fourth quarter worth $46,000. Finally, Rise Advisors LLC acquired a new position in Repligen during the fourth quarter worth $52,000. Institutional investors own 86.25% of the company’s stock.

Repligen Company Profile (Get Rating)

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

Further Reading

Earnings History and Estimates for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.